Clinical Trial: Safety of KAI-9803 for Injection with Angioplasty following Heart Attack

This study is currently recruiting patients.

Sponsored by: KAI Pharmaceuticals
Information provided by: KAI Pharmaceuticals


Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce the damage to the muscle that occurs with a heart attack. However, up to 25-50% of patients who have angioplasty may have ongoing damage to the heart muscle when the blockage is opened and blood flow is restored. Complications which may result from this ongoing damage include a larger area of damaged muscle in the heart, enlargement of the heart, an increased risk of death, and an increased risk of heart failure. Some of the ongoing damage may involve increased levels of the protein kinase C (PKC) enzyme. KAI-9803 is a selective inhibitor of delta PKC. In this study, delta PKC is used with angioplasty and other standard procedures to restore blood flow after a heart attack. This study is designed to evaluate safety of different amounts of KAI-9803 when used in treating heart attack patients undergoing angioplasty. We will also try to evaluate whether KAI-9803 can reduce the amount of heart muscle damage and the complications that may occur in these patients.

Condition Treatment or Intervention Phase
Myocardial Infarction
 Drug: KAI-9803 for Injection
Phase I
Phase II

MedlinePlus related topics:  Heart Attack

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study

Official Title: Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction

Further Study Details: 

Expected Total Enrollment:  150

Study start: September 2004


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


Inclusion Criteria:

  • Symptoms of cardiac ischemia at rest or with increasing frequency (angina or angina equivalent), with episodes lasting for at least 30 minutes within 6 hours of presentation
  • Persistent ST-segment elevation of ≥ 0.2 mV in at least 2 contiguous precordial leads indicative of anterior Myocardial Infarction (MI) location (leads V1-V4)
  • At least 18 years old
  • Complete occlusion of the left anterior descending artery (TIMI 0-1 flow) demonstrated on the initial angiogram
  • Culprit lesion suitable for primary percutaneous coronary intervention (PCI)

Exclusion Criteria:

  • Any left bundle branch block (new or old), intraventricular conduction defect, or paced rhythm that would obscure the diagnosis of acute anterior ST Elevation Myocardial Infarction (STEMI)
  • Any prior documented MI, including wild Q waves documented on prior ECGs or a clinical history of definite MI
  • Any prior coronary artery bypass grafting (CABG)
  • Cardiogenic shock at initial hospital presentation, consisting of persistent hypotension (systolic blood pressure < 90 mm Hg for > 20 minutes) and signs of end-organ dysfunction (oliguris, altered mental status, poor peripheral perfusion, and lactic acidosis)
  • TIMI grade 2 or 3 flow in the left anterior descending artery documented on the initial diagnostic angiogram
  • Culprit lesion in the left anterior descending artery that is not suitable for primary PCI
  • Treatment with intravenous fibrinolytic therapy (i.e. altepase, reteplase, tenecteplase, or streptokinase) within the 24 hours before presentation
  • Pregnancy
  • Know baseline creatinine > 2.5 mg/dL without renal dialysis/renal replacement therapy within the 30 days before presentation
  • Inability to comply with study procedures, inability to undergo cardiac catheterization or primary PCI
  • Participation in a study of experimental therapy (drug or device) within 30 days of presentation, or prior participation in this study

Location and Contact Information

Matthew Roe, MD      (919) 668-8612

North Carolina
      Duke Clinical Research Institute, Durham,  North Carolina,  27715,  United States; Recruiting

More Information

Study ID Numbers:  KAI-9803-001
Record last reviewed:  October 2004
Last Updated:  October 13, 2004
Record first received:  October 4, 2004 Identifier:  NCT00093197
Health Authority: United States: Food and Drug Administration processed this record on 2005-04-08

Cache Date: April 9, 2005